A dual-target approach, simultaneously inhibiting GLS1 (with CB-839) and c-Myc (with MYCi975), achieved stronger suppression of the GLS1-c-Myc axis, than either agent alone in an orthotopic mouse model of HNSCC. This evidence concerns the gene MYC and head and neck squamous cell carcinoma.